Version 2.1.1.0

Abstract

Grant Number:	1R43NS046174-01
PI Name:	WANG, FONG LIU.
PI Email:	fliu@novascreen.com
PI Title:
Project Title:	Novel Molecules to Treat Parkinson's Disease

Abstract: DESCRIPTION (provided by applicant): Parkinson's disease is characterized by a progressive degeneration of dopaminergic neurons of the nigrostriatal pathway. Current treatments for Parkinson's disease are dependent upon dopamine replacement therapy. After long-term dopamine replacement therapy, patients experience a "wearing-off" and "on-off" response fluctuation to the therapy. An alternative approach to treating Parkinson's disease would be to target non-dopaminergic receptors and identify selective compounds either as monotherapies or as adjuncts with L-DOPA or other dopamine agonists. Adenosine modulates basal ganglia neurotransmission by an adenosine A2A receptor-mediated mechanism. This Phase I proposal focuses on a new systematic discovery approach using combined in silico and in vitro screening. We believe this approach is useful and is likely to be successful in finding lead compounds with potent and highly selective activities at adenosine receptor A2A, A2A-D1 or A2A-D2 receptor or receptors. These lead compounds will then be further developed into drugs useful in treating Parkinson's disease.

Thesaurus Terms:
Parkinson's disease, antiparkinson drug, cell surface receptor, chemical structure function, dopamine receptor, drug design /synthesis /production, purinergic receptor
G protein, computer simulation, dopamine agonist, dopamine antagonist, receptor expression
chemical registry /resource, statistics /biometry

Institution:	NOVASCREEN BIOSCIENCES CORPORATION
	7170 STANDARD DR
	HANOVER, MD 21076
Fiscal Year:	2003
Department:
Project Start:	15-APR-2003
Project End:	30-SEP-2003
ICD:	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
IRG:	ZRG1

---